Publication | Closed Access

Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore

ThrombosisCyp2c19-guided Antiplatelet TherapyCardiovascular DiseaseAtherosclerosisOutcomes ResearchPharmacotherapyAcute Myocardial InfarctionPublic HealthPlatelet AntagonistMedicineAnticoagulantCardiologyAcute Coronary SyndromesEmergency MedicineCoronary Artery Disease